US · IMCR
Immunocore Holdings plc
- Sector
- Healthcare · Biotechnology
- Headquarters
- Abingdon OX14 4RY
- Website
- immunocore.com
Price · as of 2025-12-31
$28.16
Market cap 1.64B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $68.91 | +144.71% |
| Intrinsic Value(DCF) | $16.75 | -40.52% |
| Graham-Dodd Method(GD) | $4.95 | -82.44% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $37.63 | $47.92 | $0.00 | $0.00 | $0.00 |
| 2021 | $25.77 | $37.01 | $1.43 | $0.00 | $0.00 |
| 2022 | $51.39 | $101.90 | $30,970.72 | $3.60 | $0.00 |
| 2023 | $61.61 | $78.73 | $39,391.78 | $1.89 | $0.00 |
| 2024 | $29.80 | $58.29 | $908.56 | $3.13 | $0.00 |
| 2025 | $32.67 | $68.91 | $13.83 | $4.95 | $0.00 |
AI valuation
Our deep-learning model estimates Immunocore Holdings plc's (IMCR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $68.91
- Current price
- $28.16
- AI upside
- +144.71%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$16.75
-40.52% upside
Graham-Dodd
$4.95
-82.44% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IMCR | Immunocore Holdings plc | $28.16 | 1.64B | +145% | -41% | -82% | — | -46.31 | 4.32 | 5.53 | 2128.75 | — | 4.32 | 97.91% | -11.34% | -8.88% | -9.58% | 14.46% | -3.42% | 0.11 | -2.77 | 4.04 | 3.80 | -1095.49 | -4804.00% | 2010.00% | -15893.00% | -0.75% | -0.03 | 5.28% | 0.00% | 0.00% | 24.39% | -24.43 | -66.96 | 2.77 | 1.37 |
| ABCL | AbCellera Biologics Inc. | $3.61 | 1.08B | +1,038% | -58% | -83% | — | -7.79 | 1.18 | 15.19 | -5.71 | — | 1.30 | 100.00% | -288.98% | -194.88% | -14.47% | -29.60% | -10.78% | 0.29 | — | 11.32 | 9.21 | -0.98 | -1091.00% | 16056.00% | -689.00% | -15.25% | -2.04 | -28.78% | 0.00% | 0.00% | 0.00% | -4.09 | -5.10 | 11.82 | 2.19 |
| BHVN | Biohaven Ltd. | $11.52 | 1.22B | — | — | — | — | -3.22 | 6.43 | — | -2.59 | -5.20 | 6.75 | 0.00% | — | — | -198.83% | -3466.81% | -150.03% | 0.09 | — | 3.49 | 3.17 | 0.07 | 6195.00% | — | 7519.00% | -21.53% | -3.78 | -2297.22% | 0.00% | 0.00% | 0.00% | -2.57 | -3.88 | — | 1.47 |
| CLDX | Celldex Therapeutics, Inc… | $30.09 | 2B | +2% | -54% | — | +767% | -7.71 | 3.78 | 1330.00 | -5.79 | -13.03 | 3.99 | 100.00% | -19160.00% | -17253.33% | -40.62% | -1576.31% | -37.63% | 0.00 | — | 10.49 | 10.21 | 0.10 | 5918.00% | -7863.00% | 3379.00% | -10.71% | -4.14 | -1171.86% | 0.00% | 0.00% | 0.10% | -5.15 | -6.92 | 985.84 | 16.46 |
| HRMY | Harmony Biosciences Holdi… | $28.54 | 1.64B | +155% | +609% | +1% | +178% | — | 1.91 | 1.91 | 4.41 | — | 2.13 | 77.16% | 24.00% | 18.27% | 0.00% | 43.46% | 0.00% | 0.28 | 14.23 | 3.60 | 3.46 | -2.01 | 797.00% | 2151.00% | 5909.00% | 20.94% | 1.38 | 98.30% | 0.00% | — | 14.52% | 5.40 | 3.24 | 1.30 | 4.50 |
| JANX | Janux Therapeutics, Inc. | $13.61 | 818.61M | +171% | -7% | -80% | — | — | 0.87 | 83.16 | 0.99 | — | 0.87 | 79.71% | -1576.67% | -1576.67% | 0.00% | -954.78% | 0.00% | 0.02 | — | 39.04 | 38.67 | 0.27 | 4297.00% | -555.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 0.00% | 0.72 | — | -11.28 | 11.29 |
| MNKD | MannKind Corporation | $3.28 | 1.01B | +882% | +28% | — | -83% | 158.21 | -18.18 | 2.66 | 29.19 | — | -7.50 | 82.47% | 11.12% | 1.68% | -9.03% | -19.22% | 0.99% | -0.92 | 2.81 | 1.70 | 1.23 | -1.01 | -7942.00% | 2223.00% | -5829.00% | 1.48% | 0.11 | -6.78% | 0.00% | 0.00% | 3.16% | 20.70 | 58.68 | 2.30 | -4.20 |
| NUVB | Nuvation Bio Inc. | $5.91 | 2.02B | — | — | — | — | -0.96 | 1.17 | 68.96 | -0.09 | -0.19 | 1.18 | 10.10% | -7527.33% | -7213.76% | -106.27% | 3695.49% | -97.74% | 0.02 | -1737.91 | 9.04 | 8.91 | 0.05 | 50286.00% | — | 9183.00% | -24.05% | -2.24 | 814.24% | 0.00% | 0.00% | 0.00% | -0.08 | -0.38 | 6.24 | -0.68 |
| SION | Sionna Therapeutics, Inc. | $36.54 | 1.63B | — | — | — | — | -11.64 | -4.39 | — | -8.30 | -37.90 | -4.39 | 0.00% | — | — | 44.29% | 31.75% | -51.90% | -0.06 | — | 14.49 | 14.16 | 0.40 | 3071.00% | — | 1785.00% | -7.36% | -5.07 | 23.77% | 0.00% | 0.00% | 0.00% | -8.22 | -10.98 | — | -0.48 |
| VERA | Vera Therapeutics, Inc. | $40.79 | 2.86B | — | — | — | — | -8.67 | 4.29 | — | -6.55 | -12.48 | 4.29 | 0.00% | — | — | -50.71% | 1508.68% | -43.10% | 0.13 | — | 13.64 | 13.37 | 0.93 | 6945.00% | — | 7820.00% | -9.31% | -4.51 | 1156.04% | 0.00% | 0.00% | 9.22% | -6.21 | -8.10 | — | 10.20 |
| XERS | Xeris Biopharma Holdings,… | $6.12 | 1.02B | +379% | +286% | — | — | -11.35 | -21.01 | 3.06 | -58.75 | — | -4.11 | 81.86% | -16.57% | -27.00% | 301.32% | -20.18% | -16.99% | -9.17 | -1.01 | 1.67 | 1.12 | -14.28 | -1778.00% | 2389.00% | -2321.00% | -6.08% | -0.37 | -23.64% | 0.00% | 0.00% | 0.60% | -24.44 | -21.72 | 4.05 | -1.32 |
About Immunocore Holdings plc
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
- CEO
- Bahija Jallal
- Employees
- 493
- Beta
- 0.78
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($16.75 ÷ $28.16) − 1 = -40.52% (DCF, example).